Salute e Benessere
Third quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and strengthens financing structure
- IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025.
Performance year-to-date is on track with , i.e. at least €25 million Group REBIT underpinned by a positive REBIT from Proton Therapy.
Besides, the company further reiterates the communicated early April at the Capital Markets Day:
IBA is highly confident in its ability to deliver sustained profitability, whilst acknowledging that the realization of such long-term guidance is always prone to external risks. Therefore, we continue to closely monitor the evolving geopolitical landscape, particularly developments related to US tariffs and Chinese market restrictions for European medical devices, remaining agile in relation to potential opportunities and challenges on our business fundamentals.
***ENDS***
Catherine Vandenborre, Chief Financial Officer, and Thomas Pevenage, Head of Investor Relations, will host an online call conducted in English to discuss the Third Quarter 2025 Business Update, followed by a Q&A session.
The conference call will be held on Thursday, 20 November 2025 at 4:30pm CET / 3:30pm BST / 10:30am EDT / 7:30am PDT as a Teams webinar.
To attend the webcast, register via this link. Please complete the registration at least 15 minutes before the start of the event.
Full Year Results 2025 March 2026
Business Update First Quarter 2026 21 May 2026
Half Year Results 2026 27 August 2026
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, headquartered in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
unaudited
Proteus PLUS and Proteus ONE are brand names of Proteus®235
at pre-publication stage
Radiotherapy comparative effectiveness (RadComp) Consortium Trial
Important Projects of Common European Interest
i.e. close to worldwide GDP growth
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti